BIOLASE Stock (NASDAQ:BIOL)


RevenueOwnershipFinancialsChartTranscripts

Previous Close

$0.06

52W Range

$0.04 - $3.85

50D Avg

$0.07

200D Avg

$0.39

Market Cap

$2.20M

Avg Vol (3M)

$835.81K

Beta

0.66

Div Yield

-

BIOL Company Profile


BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, pain therapy, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces, and teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.

Show More

Industry

Medical - Devices

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

157

IPO Date

Nov 12, 1992

Website

BIOL Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Laser Systems$30.04M$31.44M$25.02M
Consumable And Other$13.60M$11.32M$9.46M
Service$5.53M$5.70M$4.71M

Fiscal year ends in Dec 23 | Currency in USD

BIOL Financial Summary


Dec 23Dec 22Dec 21
Revenue$49.16M$48.46M$39.19M
Operating Income$-17.94M$-25.34M$-16.12M
Net Income$-37.62M$-28.63M$-16.16M
EBITDA$-17.94M$-24.84M$-15.72M
Basic EPS$-29.44$-413.19$-273.41
Diluted EPS$-29.44$-413.19$-273.40

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q1 24May 13, 24 | 10:28 PM
Q4 23Mar 21, 24 | 6:35 PM
Q3 23Nov 09, 23 | 12:00 AM

Peer Comparison


TickerCompany
PACBPacific Biosciences of California, Inc.
TLISTalis Biomedical Corporation
TIVCTivic Health Systems, Inc.
NUWENuwellis, Inc.
NNOXNano-X Imaging Ltd.
BVSBioventus Inc.
DXCMDexCom, Inc.
BBLGBone Biologics Corporation
BJDXBluejay Diagnostics, Inc.
TNDMTandem Diabetes Care, Inc.
HSCSHeart Test Laboratories, Inc.
VVOSVivos Therapeutics, Inc.
NAOVNanoVibronix, Inc.